Hep-druginteractions

Hep-druginteractions assesses potential drug–drug interactions affecting antiviral therapy for hepatitis C virus (HCV) by analyzing interactions between ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) and concomitant medications to inform effects on virologic outcomes (HCV RNA).

Key Features:

• Drug interaction assessment: Systematically analyzes potential interactions between HCV therapies (OBV/PTV/r ± DSV ± RBV) and concomitant medications.
• Empirical dataset integration: Incorporates data from a multicentre study of 209 Polish patients to provide evidence-based interaction assessments.
• HCV RNA monitoring: Evaluates virologic outcomes using HCV RNA measurements at multiple time points.
• Polypharmacy stratification: Categorizes patients by number of concomitant medications and reports impacts on therapy modifications (15.8% required changes) and sustained virologic response rates (95.1%–100.0%).

Scientific Applications:

• Risk evaluation: Identifies patients at risk for clinically significant drug–drug interactions that could compromise antiviral efficacy.
• Treatment optimization: Informs decisions on modifying antiviral regimens based on expected interactions, as evidenced by 15.8% of patients requiring changes.
• Outcome monitoring: Assesses the relationship between concomitant medication use and sustained virologic response rates (95.1%–100.0%).

Methodology:

Uses data from a multicentre study of 209 Polish HCV-infected patients treated with OBV/PTV/r ± DSV ± RBV, including categorization by number of concomitant medications and serial HCV RNA measurements at multiple time points.